Emerging treatments like rusfertide may reduce phlebotomies and improve life for patients with polycythemia vera, according ...

Ionis grants Ono global rights to sapablursen for polycythemia vera in a deal worth up to $940M, including milestones and royalties on future sales.

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license agreement in which Ono obtains exclusive global ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Sapablursen and ION356 granted fast track designation by the FDA for the treatment of patients with polycythemia vera (PV) and Pelizaeus-Merzbacher disease (PMD), respectively ...

Polycythemia vera is a classic myeloproliferative neoplasm and a chronic type of leukemia, which often leads to overproduction of various blood cells. Several medications are approved to treat ...

Medically reviewed by Anju Goel, MD Blood cancers, a category that includes polycythemia vera (PV), are a risk factor for severe COVID-19. As such, managing your risk and taking steps to prevent ...

Polycythemia vera is a rare blood cancer in which bone marrow makes too many red blood cells. Photo Illustration: KATERYNA KON/Science Photo Library/Getty Images.

About BESREMi® (ropeginterferon alfa-2b) in Polycythemia Vera (PV) BESREMi® is an innovative, monopegylated, long-acting interferon that has marketing authorization in over 40 countries, ...

Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono March 12, 2025 — 07:54 am EDT. ... an investigational RNA-based therapy for polycythemia vera (PV).